On Friday, Asensus Surgical Inc. (NYSE:ASXC) saw a surge in trading as KARL STORZ Endoscopy-America, Inc. agreed to acquire the company for $0.35 per share in cash. KARL STORZ is a global medical technology company based in Germany, and the acquisition represents a significant premium for Asensus shareholders. The transaction, which is expected to close in the third quarter of 2024, will enhance KARL STORZ’s position in the robotic surgical market with the development of the next-generation LUNA system. Asensus has already secured a loan from KARL STORZ to support operations during the transaction process. Despite generating first-quarter revenues of $1.1 million, ASXC shares surged by 41.40% on Friday. This acquisition marks a significant milestone for Asensus Surgical as it becomes a subsidiary of KARL STORZ Endoscopy-America and transitions out of public trading on the NYSE American Exchange.